GMAB — Genmab A/S

Genmab Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: Increased by 19% year-over-year to $3.7 billion, driven by royalties and sales from proprietary medicines.
• Sales of Proprietary Medicines: Totaled $632 million, a 54% increase year-over-year, with EPKINLY sales reaching $468 million (up 67%).
• Operating Profit: Rose to $1.26 billion, reflecting strong execution and operational leverage.
• 2026 Guidance: Expected total revenue growth of 14%, with operating profit projected at $1.15 billion at the midpoint.

2. Strategic Updates and Business Highlights

• Pipeline Development: Continued focus on late-stage assets, notably EPKINLY, Rina-S, and petosemtamab, with significant milestones achieved in 2025.
• EPKINLY: Gained FDA approval for second-line follicular lymphoma and is positioned as a core therapy in B-cell malignancies.
• Rina-S: Expanded development with three Phase III trials initiated in gynecologic cancers.
• Merus Acquisition: Enhanced late-stage portfolio with petosemtamab, which has shown promising data in head and neck cancer.
• Commercial Expansion: Successfully launched TIVDAK in new markets, including Germany, the U.K., and France.

3. Forward Guidance and Outlook

• 2026 Expectations: Anticipate pivotal data readouts for EPKINLY, Rina-S, and petosemtamab, which could lead to multiple product launches in 2027.
• Market Opportunities: EPKINLY is expected to expand its addressable patient population significantly, with potential blockbuster status anticipated.
• Investment Strategy: Continued focus on strategic investments to support growth while maintaining profitability.

4. Bad News, Challenges, or Points of Concern

• EPCORE DLBCL-1 Trial Results: While the trial showed positive progression-free survival (PFS), it missed overall survival (OS) significance, raising questions about its regulatory implications.
• Regulatory Uncertainty: Ongoing discussions with health authorities regarding the confirmatory studies for EPKINLY and the impact of COVID-19 on trial results.
• Competitive Landscape: Concerns about competing therapies, particularly in the DLBCL space, and the need to demonstrate superior efficacy compared to existing treatments like POLIVY.

5. Notable Q&A Insights

• Regulatory Strategy for EPKINLY: Management expressed confidence in securing regulatory approvals based on upcoming Phase III data, despite challenges from previous trial results.
• Market Dynamics: The commercialization team noted strong physician feedback and uptake for EPKINLY, emphasizing its differentiated profile in the market.
• Future Trials: Discussions highlighted the importance of upcoming pivotal data for Rina-S and petosemtamab, with management optimistic about their potential to meet or exceed current treatment standards.
• Sales and Marketing Investments: Management remains disciplined in operational expenditures while preparing for potential product launches, indicating a strategic approach to scaling operations.

In summary, Genmab's strong financial performance in 2025, coupled with strategic advancements in its pipeline and commercialization efforts, positions the company favorably for future growth despite some regulatory and competitive challenges.